Teva receives the Klaus Tschira Human Resources Innovation Award

SAP SE, a German-based European multinational software corporation, announced Teva Pharmaceutical Industries as the 2018 recipient of the Klaus Tschira Human Resources Innovation Award.

FDA delays approval of Teva and Celltrion biosimilar drug due to manufacturing issues

fda office
According to a statement on Celltrion’s website, the FDA has requested supplementary information about the products.

Bayer, Novartis and Teva topped February sales rankings in Russia

According to DSM Group, in February 2018, the commercial market of medicinal products amounted to 80.6 billion rubles (in retail prices). Compared to January 2018, the market volume increased by 4.0%.

Teva will receive $700 million from Allergan

Allergan PLC, headquartered in Dublin, Ireland, a global pharmaceutical company, will pay Teva Pharmaceutical Industries Ltd. $700 million to dismiss a dispute between the two companies

Teva undertakes a restructuring process

Teva Pharmaceutical Industries Ltd. announced a new organization and leadership structure aimed to achieve better commercial focus and drive value creation

Teva appointed Kare Schultz as new CEO and Company’s President

Teva Pharmaceutical Industries Ltd. today announced that its Board of Directors has named Kare Schultz to become the Company’s President

Teva has long-term plans for the Russian market

In its financial report for Q2 2017, Teva announced that it was curtailing the activities in 45 countries

EC suspects Teva in EU antitrust rules violation

The European Commission has informed pharmaceutical company Teva of its preliminary view that an agreement concluded with Cephalon was in breach of EU antitrust rules

Teva lost a patent case to GSK and must pay $235 million

A US court yesterday ordered Teva Pharmaceutical Industries Ltd. to pay $235 million compensation to GlaxoSmithKline for violation of the latter's patent

Teva reports positive results for Phase III of migraine drug study

Teva Pharmaceutical Industries Ltd. yesterday announced positive results from a Phase III HALO study of fremanezumab

Teva launched an anti-asthmatic drug onto the Russian market

Teva announced the registration of Cinqaero, a unique innovative drug to treat severe, uncontrolled, eosinophilic asthma in adults.

Teva received warning letter from FDA

The FDA has nailed another Teva manufacturing facility with a warning letter, this one for an API facility in China. The Israel-based drugmaker informed that the letter had been issued April 10, foll...

FDA approved Teva’s neurological drug

The FDA has approved Teva’s Huntington’s Disease drug, the first new treatment for the neurological disease in almost a decade. Austedo (deutetrabenazine) tablets for the treatment of chorea associate...

Next 4 months will be most noteworthing in Teva’s history

"The next four months will be the most interesting in the history of Teva as an innovative company – more than all of its over 100 years of history," Teva Pharmaceutical Industries Ltd.  head of globa...

Teva will participate in EAEU pilot project for drug registration

Bringing the medicinal products to the territory of all EAEU member states requires practical experience of working under EAEU rules for registration and expert examination of medicinal products. Unti...

Teva is under suspicion in bribery

According to Haarez portal, the Police of Israel is investigating Teva on suspicion in bribery. The police’s national fraud unit has launched an investigation into suspicions that Teva Pharmaceutical...